Moderna stock surges after releasing promising coronavirus vaccine trial data
5 years ago 1 min read
Moderna’s stock surged early Wednesday after the biotech company said its potential coronavirus vaccine generated a promising immune response in an early-stage human trial.
More Stories
Record Korean Cases; Trader’s Guide to Rollout: Virus Update
California Hits Record; Trader’s Guide to Rollout: Virus Update
AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push